1. 373OResults of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM). (23rd October 2018) Authors: Peereboom, D; Nabors, L B; Kumthekar, P; Badruddoja, M; Fink, K; Lieberman, F; Phuphanich, S; Dunbar, E; Walbert, T; Schiff, D; Tran, D D; Ashby, L S; Butowski, N; Iwamoto, F; Lindsay, R; Bullington, J; Schulder, M; Sherman, J; Brooks, C; Reardon, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗